The company announced positive preliminary data from the VITALIZE Phase 2B trial evaluating its lead DPX product, maveropepimut-S (“MVP-S”), in combination with pembrolizumab in patients with relapsed, refractory Diffuse Large B Cell Lymphoma (“r/r DLBCL”).
- Early analysis reveals clinically meaningful activity in refractory DLBCL patients
- Multiple confirmed complete responses observed in heavily pre-treated patients
- No adverse safety and tolerability signal reported, consistent with previous clinical trials
